Lumida
/ERAS
⌘K
Erasca Inc

Erasca Inc

ERAS
$18.03USD-7.49%-1.46 today

MARKET CAP

6.3B

P/E (TTM)

FWD P/E

DAY RANGE

$18 – $20

52W RANGE

$1
$24

AI Summary

Stalk
TrimMedium

ERAS has broken below a key support zone, confirming a Stage 3 distribution context. Support failure signals further downside with price trading below declining EMAs. Medium-term bias is bearish, favoring sell opportunities on rallies into the former $18.10 support (now resistance) around dynamic EMA levels. Short-term extension below EMAs suggests deferred execution, recommending Trim at resistance retests.

  • Phase 1 AURORAS-1 trial reports 57% ORR for ERAS-0015 monotherapy
  • Raised $632.5M in public offering, total cash ~ $1.02B funding trials through 2027
  • Q2 2026 net loss of $44.1M underscores ongoing unprofitability
Full analysis →
Insider Trades5 trades
DateSideTickerInsiderRoleSharesPriceMkt Cap52W High52W LowValue% ChgRuleAI View
Apr 1, 2026SellERASEbun GarnerChief Legal Officer160,000$9.05$6.3B-25.74%+1255.54%$1.4M+0.00%10b5-1Buy Now
Mar 4, 2026SellERASShannon MorrisChief Medical Officer40,000$8.37$6.3B-25.74%+1255.54%$334.8K+0.00%10b5-1Buy Now
Dec 15, 2025BuyERASEbun GarnerGeneral Counsel & Corp. Sec.243,902$3.61$6.3B-25.74%+1255.54%$879.5K+0.71%10b5-1Buy Now
Dec 5, 2023BuyERASJonathan E LimChairman & CEO1,000,000$1.70$6.3B-25.74%+1255.54%$1.7M+4.03%Buy Now
Oct 5, 2023BuyERASJonathan E LimChairman & CEO1,000,000$2.03$6.3B-25.74%+1255.54%$2.0M+5.42%Buy Now